How does your antibody compare?

Paste its variable domains. We number them, assign their germline, fold the Fv, and compute what a developability review asks for: solvent exposure and aggregation propensity per residue, surface hydrophobicity and charge, chemical liability motifs graded by exposure, MHC-II presentation across seven DRB1 alleles, and humanness with a proposed humanised variant. Twenty-six molecule-level numbers come with their percentile among 906 clinical-stage antibodies, and everything that can be placed on a residue is. You get a workbook of all of it, on the page and as Excel.

Scientific overview (PDF) - what each number is, the published method behind it, and what it cannot tell you.

Your sequences and your result are deleted after 7 days. They are not shared, and they are used for nothing but your result. We keep your email address, so that we can tell you about Bionamic. The link we mail you starts the analysis and works for 72 hours. One address may ask for 5 profiles a day, since each one holds a GPU while it folds.

VH, the heavy chain's variable domain VL, the light chain's variable domain - leave empty for a single-domain antibody

The domain alone, without the constant region: about 110 to 130 residues, ending where the J region does.

No sequence to hand? Profile one of these marketed antibodies:

Trastuzumab Adalimumab Bevacizumab

Anti-HER2, for HER2-positive breast and gastric cancer; a humanized IgG1 with a kappa light chain.

A name for it - optional Your email address

A private link to your report will be sent here together with information about how to manage and remove your data.